Annual EBITDA
-$41.79 M
-$5.25 M-14.36%
September 30, 2024
Summary
- As of February 8, 2025, CTXR annual EBITDA is -$41.79 million, with the most recent change of -$5.25 million (-14.36%) on September 30, 2024.
- During the last 3 years, CTXR annual EBITDA has fallen by -$18.91 million (-82.64%).
- CTXR annual EBITDA is now -213094.39% below its all-time high of -$19.60 thousand, reached on September 30, 2012.
Performance
CTXR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$11.00 M
-$415.50 K-3.93%
September 30, 2024
Summary
- As of February 8, 2025, CTXR quarterly EBITDA is -$11.00 million, with the most recent change of -$415.50 thousand (-3.93%) on September 30, 2024.
- Over the past year, CTXR quarterly EBITDA has dropped by -$415.50 thousand (-3.93%).
- CTXR quarterly EBITDA is now -1832700.00% below its all-time high of -$600.00, reached on December 31, 2012.
Performance
CTXR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$41.79 M
-$922.00 K-2.26%
September 30, 2024
Summary
- As of February 8, 2025, CTXR TTM EBITDA is -$41.79 million, with the most recent change of -$922.00 thousand (-2.26%) on September 30, 2024.
- Over the past year, CTXR TTM EBITDA has dropped by -$922.00 thousand (-2.26%).
- CTXR TTM EBITDA is now -464188.89% below its all-time high of -$9000.00, reached on December 31, 2010.
Performance
CTXR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CTXR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.4% | -3.9% | -2.3% |
| 3 y3 years | -82.6% | -3.9% | -2.3% |
| 5 y5 years | -168.8% | -3.9% | -2.3% |
CTXR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -82.6% | at low | -52.7% | at low | -74.2% | at low |
| 5 y | 5-year | -168.8% | at low | -169.7% | at low | -161.8% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | at low | <-9999.0% | at low |
Citius Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | -$41.79 M(+14.4%) | -$11.00 M(+3.9%) | -$41.79 M(+2.3%) |
| Jun 2024 | - | -$10.58 M(-3.1%) | -$40.86 M(+5.0%) |
| Mar 2024 | - | -$10.92 M(+17.5%) | -$38.91 M(+0.7%) |
| Dec 2023 | - | -$9.29 M(-7.8%) | -$38.62 M(+5.7%) |
| Sep 2023 | -$36.54 M(+10.3%) | -$10.07 M(+16.8%) | -$36.54 M(+7.6%) |
| Jun 2023 | - | -$8.62 M(-18.9%) | -$33.97 M(-0.7%) |
| Mar 2023 | - | -$10.64 M(+47.7%) | -$34.21 M(+9.9%) |
| Dec 2022 | - | -$7.20 M(-4.0%) | -$31.12 M(-6.1%) |
| Sep 2022 | - | -$7.50 M(-15.4%) | -$33.14 M(+8.5%) |
| Sep 2022 | -$33.14 M(+44.8%) | - | - |
| Jun 2022 | - | -$8.87 M(+17.6%) | -$30.55 M(+11.3%) |
| Mar 2022 | - | -$7.55 M(-18.1%) | -$27.46 M(+14.5%) |
| Dec 2021 | - | -$9.22 M(+87.4%) | -$23.99 M(+4.9%) |
| Sep 2021 | -$22.88 M(+31.6%) | -$4.92 M(-14.9%) | -$22.88 M(+3.8%) |
| Jun 2021 | - | -$5.78 M(+41.7%) | -$22.04 M(+5.4%) |
| Mar 2021 | - | -$4.08 M(-49.7%) | -$20.90 M(-1.4%) |
| Dec 2020 | - | -$8.10 M(+98.7%) | -$21.20 M(+22.0%) |
| Sep 2020 | -$17.38 M(+11.8%) | -$4.08 M(-12.2%) | -$17.38 M(+2.6%) |
| Jun 2020 | - | -$4.64 M(+6.2%) | -$16.95 M(+1.5%) |
| Mar 2020 | - | -$4.37 M(+2.1%) | -$16.70 M(+4.7%) |
| Dec 2019 | - | -$4.28 M(+17.5%) | -$15.96 M(+2.7%) |
| Sep 2019 | -$15.54 M(+24.2%) | -$3.65 M(-17.2%) | -$15.54 M(+5.4%) |
| Jun 2019 | - | -$4.40 M(+21.3%) | -$14.74 M(+19.3%) |
| Mar 2019 | - | -$3.63 M(-6.3%) | -$12.36 M(-6.0%) |
| Dec 2018 | - | -$3.87 M(+36.2%) | -$13.15 M(+5.0%) |
| Sep 2018 | -$12.52 M | -$2.84 M(+40.9%) | -$12.52 M(+4.9%) |
| Jun 2018 | - | -$2.02 M(-54.3%) | -$11.93 M(-3.0%) |
| Mar 2018 | - | -$4.42 M(+36.2%) | -$12.30 M(+16.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | - | -$3.24 M(+43.5%) | -$10.61 M(+11.3%) |
| Sep 2017 | -$9.53 M(+15.0%) | -$2.26 M(-5.4%) | -$9.53 M(-3.3%) |
| Jun 2017 | - | -$2.39 M(-12.3%) | -$9.86 M(-11.0%) |
| Mar 2017 | - | -$2.72 M(+25.9%) | -$11.08 M(+20.1%) |
| Dec 2016 | - | -$2.16 M(-16.3%) | -$9.23 M(+11.4%) |
| Sep 2016 | -$8.29 M(+186.2%) | -$2.58 M(-28.4%) | -$8.29 M(+25.4%) |
| Jun 2016 | - | -$3.61 M(+315.3%) | -$6.61 M(+72.9%) |
| Mar 2016 | - | -$869.50 K(-28.8%) | -$3.82 M(+15.9%) |
| Dec 2015 | - | -$1.22 M(+34.4%) | -$3.30 M(+14.0%) |
| Sep 2015 | -$2.89 M(>+9900.0%) | -$908.30 K(+10.1%) | -$2.89 M(+45.7%) |
| Jun 2015 | - | -$825.00 K(+138.9%) | -$1.99 M(+70.8%) |
| Mar 2015 | - | -$345.30 K(-57.7%) | -$1.16 M(+34.1%) |
| Dec 2014 | - | -$816.20 K(>+9900.0%) | -$867.30 K(+53.5%) |
| Jun 2014 | - | -$1300.00(-97.4%) | -$565.00 K(-0.4%) |
| Mar 2014 | - | -$49.80 K(-90.0%) | -$567.10 K(+7.7%) |
| Dec 2013 | - | -$499.20 K(+3295.9%) | -$526.60 K(+1780.7%) |
| Sep 2013 | -$28.10 K(+43.4%) | -$14.70 K(+332.4%) | -$28.00 K(+57.3%) |
| Jun 2013 | - | -$3400.00(-63.4%) | -$17.80 K(-13.6%) |
| Mar 2013 | - | -$9300.00(+1450.0%) | -$20.60 K(+14.4%) |
| Dec 2012 | - | -$600.00(-86.7%) | -$18.00 K(-8.2%) |
| Sep 2012 | -$19.60 K(-23.4%) | -$4500.00(-27.4%) | -$19.60 K(+12.0%) |
| Jun 2012 | - | -$6200.00(-7.5%) | -$17.50 K(-4.9%) |
| Mar 2012 | - | -$6700.00(+204.5%) | -$18.40 K(-2.1%) |
| Dec 2011 | - | -$2200.00(-8.3%) | -$18.80 K(-26.6%) |
| Sep 2011 | -$25.60 K | -$2400.00(-66.2%) | -$25.60 K(+10.3%) |
| Jun 2011 | - | -$7100.00(0.0%) | -$23.20 K(+44.1%) |
| Mar 2011 | - | -$7100.00(-21.1%) | -$16.10 K(+78.9%) |
| Dec 2010 | - | -$9000.00 | -$9000.00 |
FAQ
- What is Citius Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Citius Pharmaceuticals?
- What is Citius Pharmaceuticals annual EBITDA year-on-year change?
- What is Citius Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Citius Pharmaceuticals?
- What is Citius Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Citius Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Citius Pharmaceuticals?
- What is Citius Pharmaceuticals TTM EBITDA year-on-year change?
What is Citius Pharmaceuticals annual EBITDA?
The current annual EBITDA of CTXR is -$41.79 M
What is the all time high annual EBITDA for Citius Pharmaceuticals?
Citius Pharmaceuticals all-time high annual EBITDA is -$19.60 K
What is Citius Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, CTXR annual EBITDA has changed by -$5.25 M (-14.36%)
What is Citius Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of CTXR is -$11.00 M
What is the all time high quarterly EBITDA for Citius Pharmaceuticals?
Citius Pharmaceuticals all-time high quarterly EBITDA is -$600.00
What is Citius Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, CTXR quarterly EBITDA has changed by -$415.50 K (-3.93%)
What is Citius Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of CTXR is -$41.79 M
What is the all time high TTM EBITDA for Citius Pharmaceuticals?
Citius Pharmaceuticals all-time high TTM EBITDA is -$9000.00
What is Citius Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, CTXR TTM EBITDA has changed by -$922.00 K (-2.26%)